Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study

被引:55
作者
Florakis, D [1 ]
Hung, V [1 ]
Kaltsas, G [1 ]
Coyte, D [1 ]
Jenkins, PJ [1 ]
Chew, SL [1 ]
Grossman, AB [1 ]
Besser, GM [1 ]
Monson, JP [1 ]
机构
[1] St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England
关键词
D O I
10.1046/j.1365-2265.2000.01108.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To study the effects of short (6 months) and longer-term (up to 24 months) growth hormone (GH) replacement therapy using a dose titration regimen, on lipid and glucose metabolism in GH-deficient, hypopituitary adults. DESIGN On-going open study of GH treatment up to 24 months. Measurements were performed at baseline and at 6, 12, 18 months and 2 years during therapy (data shown at 6 months and 2 years only). Using a dose titration regimen the median GH dose used to achieve and maintain IGF-I levels above the median, but below the upper limit of the age-related reference range (median IGF-I 202.5 mu g/l, range 76-397 mu g/l), was 1.2 IU daily (range 0.4-3 IU) [0.8 IU/day, males; 1.6 IU/day, females]. PATIENTS Ninety GH-deficient hypopituitary adults (54 female, median age 48 years, range 19-79 years) entered the study and 24 (14 female, median age 45 years, range 32-79 years) have concluded the 2 year period of assessment. MEASUREMENTS Body mass index (BMI), waist and hip circumference ratio (WHR), fasting lipids, glucose and glycated haemoglobin (HbA(1c)) levels were measured at 6 month intervals during GH therapy. RESULTS Using the dose titration regimen, compared to pretreatment values, total and low density lipoprotein (LDL)-cholesterol levels were significantly lower at 6 months (mean +/- SEM, 5.61 +/- 0.1 vs. 5.25 +/- 0.1, and 3.85 +/- 0.19 vs. 3.43 +/- 0.26, respectively, P < 0.05), and were maintained throughout the study. Male patients had significantly lower pretreatment total and LDL cholesterol levels than females (mean +/- SEM, 5.33 +/- 0.16 mmol/l vs. 5.7 +/- 0.12 mmol/l and 3.8 +/- 0.23 mmol/l vs. 3.92 +/- 0.29 mmol/l, respectively, P < 0.05). A decrease in total cholesterol was confined to patients with pretreatment total cholesterol levels above 5.8 mmol/l; patients with the highest pretreatment cholesterol levels (> 6.4 mmol/l) obtained the greatest cholesterol reduction (mean +/- SEM, 7.13 +/- 0.14 mmol/l vs. 5.76 +/- 0.31 mmol/l, P < 0.05). A cholesterol-lowering effect of GH therapy was evident in patients who had elevated pre-GH total cholesterol levels even if they were already receiving and continuing lipid lowering medication (mean +/- SEM, 5.62 +/- 0.22 vs. 5.03 +/- 0.285, P < 0.05). A modest increment in high density lipoprotein (HDL)-cholesterol was evident at 18 months but there was no significant change in triglycerides at any time point. Fasting plasma glucose increased significantly at 6 months but remained within the reference range. Glycated haemoglobin increased significantly at 6 months and was maintained throughout the study; one patient developed frank diabetes mellitus while receiving treatment. There was a weak but significant correlation between the increment in glycated haemoglobin and pretreatment BMI (r = + 0.215, P < 0.05). CONCLUSION The effect of GH on lowering total and low density lipoprotein-cholesterol is more prominent in patients with higher pretreatment cholesterol levels and is evident even in patients receiving other lipid-lowering medication. A modest increment in mean fasting glucose (within the reference range) and mean glycated haemoglobin persisted throughout the study. One patient developed diabetes mellitus. A GH replacement regimen using low dose and careful titration to avoid elevated IGF-I levels and adverse effects is associated with sustained beneficial effects on circulating lipids.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 29 条
[1]   GH replacement in 1034 growth hormone deficient hypopituitary adults:: demographic and clinical characteristics, dosing and safety [J].
Abs, R ;
Bengtsson, BÅ ;
Hernberg-Ståhl, E ;
Monson, JP ;
Tauber, JP ;
Wilton, P ;
Wüster, C .
CLINICAL ENDOCRINOLOGY, 1999, 50 (06) :703-713
[2]   Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults [J].
Al-Shoumer, KAS ;
Gray, R ;
Anyaoku, V ;
Hughes, C ;
Beshyah, S ;
Richmond, W ;
Johnston, DG .
CLINICAL ENDOCRINOLOGY, 1998, 48 (06) :795-802
[3]  
BATES AS, 1996, J CLIN ENDOCRINOLOGY, V76, P309
[4]   TREATMENT OF ADULTS WITH GROWTH-HORMONE (GH) DEFICIENCY WITH RECOMBINANT HUMAN GH [J].
BENGTSSON, BA ;
EDEN, S ;
LONN, L ;
KVIST, H ;
STOKLAND, A ;
LINDSTEDT, G ;
BOSAEUS, I ;
TOLLI, J ;
SJOSTROM, L ;
ISAKSSON, OGP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (02) :309-317
[5]   THE EFFECTS OF SHORT AND LONG-TERM GROWTH-HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS ON LIPID-METABOLISM AND CARBOHYDRATE-TOLERANCE [J].
BESHYAH, SA ;
HENDERSON, A ;
NITHTHYANANTHAN, R ;
SKINNER, E ;
ANYAOKU, V ;
RICHMOND, W ;
SHARP, P ;
JOHNSTON, DG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (02) :356-363
[6]   THE EFFECT OF GROWTH-HORMONE ADMINISTRATION IN GROWTH-HORMONE DEFICIENT ADULTS ON BONE, PROTEIN, CARBOHYDRATE AND LIPID HOMEOSTASIS, AS WELL AS ON BODY-COMPOSITION [J].
BINNERTS, A ;
SWART, GR ;
WILSON, JHP ;
HOOGERBRUGGE, N ;
POLS, HAP ;
BIRKENHAGER, JC ;
LAMBERTS, SWJ .
CLINICAL ENDOCRINOLOGY, 1992, 37 (01) :79-87
[7]   Increased cerebrovascular mortality in patients with hypopituitarism [J].
Bulow, B ;
Hagmar, L ;
Mikoczy, Z ;
Nordstrom, CH ;
Erfurth, EM .
CLINICAL ENDOCRINOLOGY, 1997, 46 (01) :75-81
[8]   Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review [J].
Carroll, PV ;
Christ, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) :382-395
[9]   Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy [J].
Christopher, M ;
Hew, FL ;
Oakley, M ;
Rantzau, C ;
Alford, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1668-1681
[10]  
*CONS GUID DIAGN T, 1998, J CLIN ENDOCRINOLOGY